Category Archives: Global News Feed

Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 ?

Follow this link:
CHMP recommends RYBREVANT®? (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small...

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets.

Read the original here:
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval

The rest is here:
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

Presentation to feature Silo’s novel therapeutics for the underserved

Read the original post:
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial.

Original post:
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on...

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients

Read the rest here:
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Company to host conference call on Monday, July 29 at 8:30 a.m. ET Company to host conference call on Monday, July 29 at 8:30 a.m. ET

See the original post here:
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous...

BOSTON, July 26, 2024 (GLOBE NEWSWIRE) -- eLabNext, a leading provider of digital lab management solutions, and ABI-LAB, a premier life sciences incubator located in Natick, MA, have announced a strategic alliance aimed at driving innovation and supporting the growth of life sciences startups.

Read more:
eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences

SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for the marketing authorization application (MAA) for toripalimab (European trade name: LOQTORZI®). The CHMP recommends approval for toripalimab for two indications:

Original post:
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.

Excerpt from:
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold